Skip to main content

Table 1 Main features of the 339 reported patients

From: Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities

  Total patients (%) CF Patients (%) HS Patients (%) P Value
No. 339 141 (41.59) 198 (58.41)  
Mean age (range) 60 (22–86) 52 (22–79) 62.5 (38–86) <0.001
Histology     NS
ILC 30 (8.8) 12 (8.5) 18 (9.1)  
IDC 299 (88.2) 126 (89.4) 173 (87.4)  
Intraductal 10 (3) 3 (21) 7 (3.5)  
T stage     NS
T1 293 (86.4) 121 (85.8) 172 (86.7)  
T2 46 (13.6) 20 (14.2) 26 (13.3)  
N stage     NS
Nx 21 (6,3) 8 (5,7) 13 (6,5)  
N0 251 (74) 93 (65.9) 158 (79.8)  
N1 67 (19.7) 32 (22.6) 35 (17.6)  
Grading (Bloom Richardson’s scale)     NS
G1 60 (17.7) 22 (15.6) 38 (19.2)  
G2 131 (38.6) 58 (41.1) 73 (36.8)  
G3 79 (23.3) 36 (25.5) 43 (21.7)  
NA 69 (20.4) 25 (17.8) 44 (22.3)  
Surgical margins     NS
Negative 295 (87) 124 (87.9) 171 (86.4)  
Positive 5 (1.5) 2 (1.4) 3 (1.5)  
Close (< 2 mm) 27 (8) 10 (7.1) 17 (8.6)  
Tangents 12 (3.5) 5 (3.6) 7 (3.5)  
Breast Volume     
Average cc 718.7 684 725.4 NS
(range) (188.6-2036.7) (188.6-1899.9) (193.3-2036.7)
Chemotherapy     
Yes 126 (37.2) 68 (48.2%) 58 (29.3%)  
No 211 (62.2%) 72 (51.1%) 139 (70.2%) 0.008
NA 2 (0.6%) 1 (0.7%) 1 (0.5%)  
Hormone therapy     
Yes 247 (72.8) 101 (71.6) 146 (73.7) NS
No 74 (21.8) 34 (24.1) 40 (20,2)  
NA 18 (5.4) 6 (4.3) 12 (6.1)  
Trastuzumab     
Yes 17 (5) 7 (5) 10 (5) NS
No 327 (95) 134 (95) 188 (95)  
  1. CF: Conventional Fractionation; HS: Hypofractionated Schedule; ILC: infiltrating lobular carcinoma; IDC: infiltrating ductal carcinoma; NA: not available; NS: not significant (P>0.05).